Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome

NCT04639960 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Difficulties in recruitment of participants and end of funding

Conditions

22q11.2 Deletion Syndrome

Interventions

DRUG: Risperdal
DRUG: Placebo

Sponsor

University of Geneva, Switzerland